View Agent
| Agent Info | |
| Agent: | ridaforolimus |
| Synonyms: | Deforolimus;AP 23573;MK 8669;AP-23573;MK-8669;AP23573, MK-8669, Ridaforolimus, Deforolimus |
| Drug Status For Certain Diseases: | Sarcoma (phase III) |
| Classification: | an orally bioavailable inhibitor of the mTOR pathway |
| Target: | Serine/threonine-protein kinase mTOR |
| KEGG Pathway: | Type II diabetes mellitus Glioma Insulin signaling pathway PI3K-Akt signaling pathway mTOR signaling pathway Acute myeloid leukemia Prostate cancer MicroRNAs in cancer Pathways in cancer AMPK signaling pathway HIF-1 signaling pathway Adipocytokine signaling pathway Central carbon metabolism in cancer Choline metabolism in cancer Thyroid hormone signaling pathway |
| Wiki Pathway: | Type II diabetes mellitus TOR Signaling Interferon type I signaling pathways Cardiac Hypertrophic Response Insulin Signaling PIP3 activates AKT signaling Alpha 6 Beta 4 signaling pathway Oncostatin M Signaling Pathway TSLP Signaling Pathway Leptin signaling pathway TSH signaling pathway RANKL/RANK Signaling Pathway EGF/EGFR Signaling Pathway ErbB Signaling Pathway Signaling by Insulin receptor MicroRNAs in cardiomyocyte hypertrophy Senescence and Autophagy in Cancer Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Integrated Breast Cancer Pathway Wnt Signaling Pathway Netpath Polycystic Kidney Disease Pathway SREBP signalling FSH signaling pathway AMPK Signaling Extracellular vesicle-mediated signaling in recipient cells BDNF signaling pathway Prostate Cancer SREBF and miR33 in cholesterol and lipid homeostasis Costimulation by the CD28 family |